Replies to post #21230 on Marketgems Earnings Trader- Trading Strong or Weak (MKTGEMS)

[jenna]

TNOX newsletter good news after hours which was part of the reason we had in on today's newsletter (technical position was the other consideration)




TNX-355 Phase 1b Results Presented at 11th Conference on Retroviruses And Opportunistic Infections (CROI)
Wednesday February 11, 5:06 pm ET


HOUSTON, Feb. 11 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX - News) presented today the results from the TNX-355 multi-dose Phase 1b clinical trial in human immunodeficiency virus-1 (HIV-1)-infected patients at the 11th Conference on Retroviruses and Opportunistic Infections (CROI). The study was conducted in 22 HIV-1 infected patients. TNX-355 was either added as a new drug to their current regimen or administered as monotherapy. At screening, patients were selected with stable baseline HIV-1 RNA levels (viral load) of 5,000 copies/mL or greater and CD4+ cell counts of 100 cells/uL and higher.